News
Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...
CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal ...
(Reuters) -CureVac said on Thursday that the company and GSK have entered an agreement to a resolve patent dispute with ...
The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...
CureVac (CVAC) and GSK (GSK) to receive $740M and other payments in a settlement with Pfizer (PFE) and BioNTech (BNTX) over ...
The complex settlement, which hands payouts and royalties to CureVac and partner GSK, comes as BioNTech is inching toward an ...
The Covid-19 pandemic turned Moderna and BioNTech into household names almost overnight. Now the two companies find ...
CureVac ( (CVAC)) has provided an announcement. On August 7, 2025, CureVac announced the resolution of U.S. patent litigation with Pfizer/BioNTech concerning mRNA-based COVID-19 vaccines. As part of ...
“In the second quarter, we took significant steps to advance BioNTech into a multiproduct biotechnology company by ...
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...
Analysts have recently evaluated BioNTech and provided 12-month price targets. The average target is $134.42, accompanied by ...
BioNTech also laid off 63 employees in June in conjunction with the discontinuation of its cell therapy manufacturing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results